FLOMAX
Company: Boehringer Ingelheim
Approval Status: Approved October 1997
Treatment for: benign prostatic hypertrophy (BPH)
Areas: Nephrology/Urology
General Information
Other Useful Resources
FLOMAX has been approved for the treatment of benign prostatic hypertrophy (BPH). Boehringer Ingelheim, which licensed the product from originator Yamanouchi, will market the product in the U.S.
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
